Cicloxilic acid is a choleretic agent. Cicloxilic acid feeding lowered bile saturation (though bile tended to remain more saturated than normal) without affecting total bile acid pool size. The efficacy of cicloxilic acid in lowering biliary cholesterol saturation was not due to changes of dietary cholesterol absorption or of hepatic cholesterol synthesis. Hepatic cholesterogenesis and dietary cholesterol absorption are unaffected by cicloxilic acid feeding. Since cicloxilic acid is safe, cheap and lowers bile cholesterol saturation, this compound might have a place in gallstone disease either in association with the litholytic bile acids or in prevention of stone formation in high-risk populations (diabetics, obese, hyperlipidemic, etc.).

Ciprofibrate is an orally active phenoxyisobutyrate hypolipidemic compound. It acts by activating peroxisome proliferator activated receptor alpha. Ciprofibrate is efficacious for the correction of hyperlipidaemias.

Zolimidine, a derivate of imidazopyridine, has a gastroprotective effect. It is used in the treatment of peptic ulcer and gastro-oesophageal reflux disease.

Azintamide was initially studied as a therapeutic agent in psoriasis vulgaris. Then was shown, the drug was effective and safe in the treatment of patients with dyspepsia symptoms by the modulation of visceral sensitivity and/or gastrointestinal motility.

PIFARNINE is a non-anticholinergic gastric antisecretory drug used as anti-ulcer agent.

Dexloxiglumide is a selective antagonist of cholecystokinin receptor A (CCKA, CCK1). It is the dextro isomeric form of loxiglumide, Dexloxiglumide was investigated for treatment of irritable bowel syndrome. Its development in USA was discontinued.

Clofibride is a hypolipaemic drug of p-chlorophenoxyisobutyric type. Clofibride hypolipaemic effects could be due, partially, to a reduction of hormono-dependent lipolysis. Clofibride decreased blood cholesterol and total lipids, increased liver weight and liver catalase content, and decreased biliary excretion of cholesterol in normolipidemic rats after a 7 day treatment.

FEBUPROL is a choleretic drug.

Cyclobutyrol (CB) is a choleretic agent, which also inhibits biliary lipid secretion. Administration of cyclobutyrol reduced biliary concentration and output of cholesterol and phospholipid. This is due to an uncoupling of the secretion of cholesterol and phospholipids from that of bile acids. Biliary outputs of the canalicular membrane enzymes 5'-nucleotidase and alkaline phosphodiesterase I are depressed. The most likely effect of CB is exerted at the level of the canalicular membrane.

Carbutamide (or BZ-55) under the brand name Glucidoral was used as the anti-diabetic drug to treat diabetes in France. Carbutamide belongs to the family of sulphonylureas and reduces the excess sugar in the blood by promoting the secretion of insulin.